Does Rogers' (NYSE:ROG) Share Price Gain of 89% Match Its Business Performance?
Rogers Corporation (NYSE:ROG) shareholders might be concerned after seeing the share price drop 14% in the last...
Simply Wall St. · 5d ago
Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments
There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of...
MarketWatch · 09/18 19:48
Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients
Shares of Roche Holding AG undefined gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid...
MarketWatch · 09/18 12:42
Consumer goods drive record in seaborne imports to U.S. in August, and medical test kits may have peaked, report finds
Seaborne imports to the U.S. set a record in August and were up 5.9% from the same period a year ago, according to a new report from Panjiva, the supply...
MarketWatch · 09/09 19:21
Hedge Fund Picks at Sohn 2019 Mostly Flopped After Covid Selloff
(Bloomberg) -- Only a few winners have emerged among the hedge-fund managers and short-sellers who pitched their top trade ideas at last year’s Sohn Investment Conference in Hong Kong, after markets were rocked by the coronavirus outbreak.WT Asset Management’s Wang Tongshu is the clear standout, with
Bloomberg · 09/08 23:00
Sanofi, Regeneron: Kevzara fails in late-stage COVID-19 trial
Shares of Sanofi undefinedundefined were up 0.9% in premarket trading on Tuesday after the drugmaker said that the rheumatoid arthritis drug Kevzara failed a...
MarketWatch · 09/01 13:39
Rogers Corporation's (NYSE:ROG) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Rogers (NYSE:ROG) has had a rough month with its share price down 11%. However, stock prices are usually driven by a...
Simply Wall St. · 08/27 20:27
PTC reports first milestone payment from Roche for spinal muscular atrophy drug
Shares of PTC Therapeutics Inc. undefined were down 0.9% in trading on Wednesday after the company said it received its first milestone payment of $20...
MarketWatch · 08/26 14:44
ImmunoGen: Turning Around In A Coronavirus Environment
ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.
Seeking Alpha - Article · 08/25 18:03
FDA approves Roche's new spinal muscular atrophy drug
Roche Holding AG said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It's the second drug to be approved by the regulator to treat the rare disease. The therapy was devel
MarketWatch · 08/08 14:40
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,0
MarketWatch · 08/07 13:11
Rogers Corporation Introduces Griswold GripON™, an Advanced Line of Adhesive-Backed, Pressure Sensitive Materials
Rogers Corporation today announced the launch of Griswold GripON™, a next generation natural sponge solution designed to address slippage and skidding issues prominent within the electronics, furniture, automotive, and appliances industries. Engineered to redu
PR Newswire · 08/05 14:53
Did Hedge Funds Make The Right Call On Rogers Corporation (ROG)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 08/04 15:00
Rogers under pressure post Q2 earnings
Seeking Alpha · 07/31 04:00
Rogers Corp. (ROG) Q2 Earnings Beat Estimates
Rogers Corp. (ROG) delivered earnings and revenue surprises of 25.56% and -2.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/31 00:10
Rogers Sees Q3 Adj. EPS $0.90-$1.10 vs $1.05 Estimate, Sales $175M-$190M vs $202M Est.
Benzinga · 07/30 20:55
Rogers Q2 Adj. EPS $1.13 Beats $0.90 Estimate, Sales $191.20M Miss $197.10M Estimate
Rogers (NYSE:ROG) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.90 by 25.56 percent. This is a 31.1 percent decrease over earnings of $1.64 per share from the same period
Benzinga · 07/30 20:54
Rogers Corporation Reports Second Quarter 2020 Results
Q2 2020 Earnings Release
Business Wire · 07/30 20:09
Roche eliminates 474 positions
Genentech, a subsidiary of Roche Holding AG , confirmed that it eliminated 474 positions in July in the U.S. Roche's stock was down in trading on Thursday. "These position eliminations are not related to the COVID-19 pandemic, the clinical trials for which Act
MarketWatch · 07/30 15:15
Rogers EPS beats by $0.23, misses on revenue
Seeking Alpha · 07/30 04:00
Webull provides a variety of real-time ROG stock news. You can receive the latest news about Roger through multiple platforms. This information may help you make smarter investment decisions.
About ROG
Rogers Corporation manufactures and sells engineered materials and components for mission critical applications. The Company's segments are Advanced Connectivity Solutions (ACS), Elastomeric Material Solutions (EMS), Power Electronics Solutions (PES) and Other. The ACS segment manufactures and sells circuit materials and solutions for applications in wireless communications infrastructure, automotive, connected devices, consumer electronics and aerospace/defense. The EMS segment manufactures and sells elastomeric material solutions for critical cushioning, sealing, impact protection and vibration management applications, including general industrial, portable electronics, consumer goods, automotive, construction and printing applications. The PES segment manufactures and sells ceramic substrate materials for power module applications, laminated bus bars for power inverter and interconnect applications, and micro-channel coolers. Its other business consists of elastomeric components.